Significant Customers and Concentrations of Risk

12 Months Ended

Dec. 31, 2017

Risks And Uncertainties [Abstract]

Significant Customers and Concentrations of Risk

11. Significant Customers and Concentrations of Risk

Revenues by customer geographic location are summarized as follows:

	For the Years Ended December 31,
	2017		2016		2015
United States of America	$	48,924	$	45,531	$	39,229
Europe		5,061		6,117		6,026
Other		530		574		403
	$	54,515	$	52,222	$	45,658

Significant customers from which the Company derived 10% or more of its total revenue in any of the periods presented are as follows: 

	For the Years Ended December 31,
	2017		2016		2015
Teva	$	20,949	$	24,941	$	17,715
AMAG		8,965		4,446		365
McKesson (1)		8,707		7,600		6,837
AmerisourceBergen(1)		6,098		4,903		4,527
Ferring		5,258		6,283		6,117
LEO Pharma		—		—		6,000

⁽¹⁾ Revenue net of estimated sales returns and allowances based on OTREXUP^® shipments to the distributor.